Saturday, 31 July 2021


Terumo Europe and UMCU ink MoU to develop solutions in interventional oncology

21 July 2021 | News

Acquisition of Quirem Medical in 2020 and the creation of the Global TIO team in 2021 creates great opportunities to leverage the broad Terumo technology base in interventional oncology for improved cancer care

Image credit: prnewswire

Image credit: prnewswire

Terumo Europe and University Medical Center Utrecht (UMC Utrecht) have announced that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology.

In the past years, both parties have successfully collaborated in technology transfer, product development and the advancement of clinical evidence in the field of Selective internal radiation therapy, referred to as SIRT (also known as Radioembolization, RA or Transarterial radioembolization, TARE)  for the treatment of unresectable liver tumors.

The MoU marks the continuation of the existing partnership and confirms the shared interest of both parties to enhance education and innovations to develop meaningful solutions that provide significant clinical benefits to patients with cancer and increase their access to treatments.

"With the acquisition of Quirem Medical in 2020 and the creation of the Global TIO team in 2021, we see great opportunities to leverage the broad Terumo technology base in interventional oncology for improved cancer care. The UMC Utrecht has proven a highly reliable, professional & innovative clinical partner with a strong focus on image-guided therapies in cancer care." Says Ghada Farah, Senior Vice President Terumo Interventional Systems EMEA.

Terumo, a global leader in medical technology, announced on April 12, 2021 the launch of its Global Therapeutic Interventional Oncology (TIO) team. This reflects Terumo's aspiration to be a global leader in the field of Interventional Oncology by focusing on improving patient's quality of life and survival.

"This Memorandum of Understanding underlines the collaboration that is already there for QuiremSpheres™ Holmium-166 Microspheres and the ambition to collaborate in the broader range of interventional oncology, including tumor ablation and chemoembolization." says Dr Maarten Smits, Interventional Radiologist, UMC Utrecht

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account